Freeline Therapeutics Holdings plc

General Information


We are a clinical stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, including hemophilia B. We aim to deliver one-time gene therapy treatments that provide functional cures through permanently sustained physiological protein levels, leveraging the high expression enabled by our proprietary gene therapy platform. Our initial focus is on developing treatments for monogenic diseases with high unmet need. We are a fully integrated biotechnology company with internal expertise and capability across the value chain in gene therapy, including expression platform, research, manufacturing, clinical development and commercialization. Our pipeline includes two programs in the clinic and two late-stage preclinical product candidates, as well as research programs targeting novel applications for systemic gene therapy, for which we have, through owned and in-licensed intellectual property rights, development and worldwide commercial rights.

Employees: 208
Founded: 2015
Contact Information
Address Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, United Kingdom
Phone Number +44 (0)1438 906870
Web Address
View Prospectus: Freeline Therapeutics Holdings plc
Financial Information
Market Cap $564.9mil
Revenues $0 mil (last 12 months)
Net Income $-53.9 mil (last 12 months)
IPO Profile
Symbol FRLN
Exchange NASDAQ
Shares (millions): 8.8
Price range $18.00 - $18.00
Est. $ Volume $158.8 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley/ Evercore
CO-Managers Wedbush Securities
Expected To Trade: 8/7/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change